Targeting brain cancer with a new drug combination
Brain-Restricted Kinase Inhibition with Binary Pharmacology
This study is testing a new drug combination to help treat glioblastoma, a tough type of brain cancer, by using RapaLink-1 and RapaBlock to make the treatment more effective while keeping side effects low for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11047570 on NIH RePORTER |
What this research studies
This research investigates a novel approach to treat glioblastoma, a highly aggressive brain cancer, by using a new drug called RapaLink-1 that effectively penetrates the blood-brain barrier. The study combines RapaLink-1 with another drug, RapaBlock, to enhance its effectiveness while minimizing side effects outside the brain. By focusing on the mechanistic target of rapamycin (mTOR), which is often dysregulated in glioblastoma, the research aims to improve treatment outcomes for patients with this challenging condition. The methodology includes testing this drug combination in animal models to evaluate its potency and safety.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with glioblastoma who are seeking new treatment options.
Not a fit: Patients with other types of brain tumors or those who do not have glioblastoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for glioblastoma, potentially improving survival rates and quality of life for patients.
How similar studies have performed: Previous research has shown promise in targeting mTOR pathways in glioblastoma, suggesting that this approach could be a significant advancement in treatment.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Weiss, William a — University of California, San Francisco
- Study coordinator: Weiss, William a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.